- Home
- UUU vs LNAI Comparison
UUU vs LNAI Comparison
Compare UUU & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UUU | LNAI |
|---|---|---|
| Founded | 1969 | N/A |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 11.9M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | UUU | LNAI |
|---|---|---|
| Price | $5.74 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.2K | ★ 21.4M |
| Earning Date | 02-19-2026 | 05-14-2026 |
| Dividend Yield | ★ 17.18% | N/A |
| EPS Growth | ★ 229.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $23,563,554.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.39 | N/A |
| 52 Week Low | $1.90 | $0.15 |
| 52 Week High | $8.27 | $1.66 |
Technical Indicators
Market Signals| Indicator | UUU | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 43.25 |
| Support Level | $4.00 | $0.15 |
| Resistance Level | $6.27 | $0.54 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 44.44 | 15.37 |
Price Performance
Historical ComparisonAbout UUU Universal Security Instruments Inc.
Universal Safety Products Inc is a U.S.-based importer and distributor of home safety devices such as ventilation fans and ground fault circuit interrupters.
About LNAI Lunai Bioworks Inc.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.